Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells

References

• Lothstein, L, Israel M, Sweatman TW. Anthracycline drug targeting: Cytoplasmic versus nuclear - a fork in the road. Drug Resist Updat 2001;4:169–177.
   PubMed Web of Science ®Google Scholar
• Kruk I, Michalska T, Kladny J, Kubera-Nowakowska L. Luminescence investigations of redox cycling of adriamycin. Chemosphere 2001;44:83–90.
   Google Scholar
• Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M, et al. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 2000;95:3214–3218.
   PubMed Web of Science ®Google Scholar
• Thornalley PJ. Glyoxalase I - structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 2003;31:1343–1348.
   PubMed Web of Science ®Google Scholar
• Thornalley PJ. Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methyl-glyoxal, glyoxalase I inhibitor diesters and S-D-lactoylgluta-thione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor. Grit Rev Oncol Hematol 1995;20:99–128.
   Google Scholar
• Rulli A, Carli L, Romani R, Baroni T, Giovannini E, Rosi G, et al. Expression of glyoxalase I and II in normal and breast cancer tissues. Breast Cancer Res Treat 2001;66:67–72.
   PubMed Web of Science ®Google Scholar
• Thornalley PJ, Ladan MJ, Ridgway SJ, Kang Y. Antitumor activity of S-(p-bromobenzyl)glutathione diesters in vitro: A structure-activity study. J Med Chem 1996;39;3409–3411.
   PubMed Web of Science ®Google Scholar
• Kavarana MJ, Kovaleva EG, Creighton DJ, Wollman MB, Eiseman JL. Mechanism-based competitive inhibitors of glyoxalase I: Intracellular delivery, in vitro antitumor activities, and stabilities in human serum and mouse serum. J Med Chem 1999;42:221–228.
   Google Scholar
• Creighton DJ, Zheng ZB, Holewinski R, Hamilton DS, Eiseman JL. Glyoxalase I inhibitors in cancer chemotherapy. Biochem Soc Trans 2003;31:1378–1382.
   Google Scholar
• Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T, Tsuruo T. Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Chin Cancer Res 2001;7:2513–2518.
   Web of Science ®Google Scholar
• Wu L, Eftekharpour E, Davies GF, Roesler WJ, Juurlink BH. Troglitazone selectively inhibits glyoxalase I gene expression. Diabetologia 2001;44:2004–2012.
   Google Scholar
• Wu L, Davies GF, Roesler WJ, Juurlink BHJ. Regulation of the glyoxalase pathway in human brain microvascular endothelium: Effects of tertiary-butylhydroquinone and tro-glitazone. Endothelium 2002;4:273–278.
   Google Scholar
• Laborda J. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 1991;19:3998.
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Analyt Biochem 1976;72: 248–254.
   PubMed Web of Science ®Google Scholar
• Patterson MK Jr. Measurement of growth and viability of cells in culture. Methods Enzymol 1979;58:141–152.
   PubMedGoogle Scholar
• Uliasz TF, Hewett SJ. A microtiter trypan blue absorbance assay for the quantitative determination of excitotoxic neuronal injury in cell culture. J Neurosci Methods 2000; 100:157–163.
   PubMed Web of Science ®Google Scholar
• Kaufmann WK. Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints. Proc Soc Exp Biol Med 1998;217:327–334.
   PubMed Web of Science ®Google Scholar
• Bae MA, Rhee H, Song BJ. Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxicol Lett 2003;139: 67–75.
   Google Scholar
• Motomura W, Takahashi N, Nagamine M, Sawamukai M, Tanno S, Kohgo Y, et al. Growth arrest by troglitazone is mediated by p27Kip 1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int J Cancer 2004; 108:41–46.
   PubMed Web of Science ®Google Scholar
• Yang XJ. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res 2004;32:959–976.
   PubMed Web of Science ®Google Scholar
• Meeks-Wagner D, Hartwell LH. Normal stoichiometry of histone dimer sets is necessary for high fidelity of mitotic chromosome transmission. Cell 1986;44:43–52.
   Google Scholar
• Han M, Chang M, Kim UJ, Grunstein M. Histone H2B repression causes cell-cycle-specific arrest in yeast: Effects on chromosomal segregation, replication, and transcription. Cell 1987;48:589–597.
   PubMed Web of Science ®Google Scholar
• Kim UJ, Han M, Kayne P, Grunstein M. Effects of histone H4 depletion on the cell cycle and transcription of Saccharomyces cerevisiae. EMBO J 1988;7:2211–2219.
   PubMed Web of Science ®Google Scholar
• Pascreau G, Arlot-Bonnemains Y, Prigent C. Phosphorylation of histone and histone-like proteins by aurora kinases during mitosis. Prog Cell Cycle Res 2003;5:369–374.
   PubMedGoogle Scholar
• Polioudaki H, Markaki Y, Kourmouli N, Dialynas G, Theodoropoulos PA, Singh PB, et al. Mitotic phosphorylation of histone H3 at threonine 3. FEBS Lett 2004;560:39–44.
   PubMedGoogle Scholar
• Nowak SJ, Corces VG. Phosphorylation of histone H3: Abalancing act between chromosome condensation and transcriptional activation.Trends Genet 2004;20:214–220.
   PubMed Web of Science ®Google Scholar
• Johnson CA, Turner BM. Histone deacetylases: Complex transducers of nuclear signals. Semin Cell Dev Biol 1999; 10:179–188.
   PubMed Web of Science ®Google Scholar
• Carrozza MJ, Utley RT, Workman JL, Cote J. The diverse functions of histone acetyltransferase complexes. Trends Genet 2003;19:321–329.
   PubMed Web of Science ®Google Scholar
• Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: A molecular definition. Oncogene 2004;23:2825–2837.
   PubMed Web of Science ®Google Scholar
• Castedo M, Perfettini JL, Roumier T, Valent A, Raslova H, Yakushijin K, et al. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 2004;23:4362–4370.
   PubMed Web of Science ®Google Scholar
• Hirase N, Yanase T, Mu Y, Muta K, Umemura T, Takayanagi R, et al. Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. Oncology 1999;57:17–26.
   PubMed Web of Science ®Google Scholar
• Sugimura A, Kiriyama Y, Nochi H, Tsuchiya H, Tamoto K, Sakurada Y, et al. Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun 1999;261:833–837.
   PubMed Web of Science ®Google Scholar
• Baek SJ, Wilson LC, His LC, Eling TE. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth re-sponse-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 2003;278:5845–5853.
   Google Scholar
• Romanski A, Bacic B, Bug G, Pfeifer H, Gul H, Remiszewski S, et al. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica 2004;89:419–426.
   PubMed Web of Science ®Google Scholar
• Batova A, Shao LE, Diccianni MB, Yu AL, Tanaka T, Rephaeli A, et al. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood 2002;100:3319–3324.
   PubMed Web of Science ®Google Scholar
• Kim DH, Kim M, Kwon HJ. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 2003;36:110–119.
   Google Scholar
• Fukui Y, Masui S-i, Osada S, Umesono K, Motojima K. A new thiazolidinedione, NC-2100, which is a weak PPAR-y activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes 2000;49: 759–767.
   Google Scholar
• Wilson TM, Cobb JE, Cowan DJ, et al. The structure-activity relationships between peroxisome proliferators-activated re-ceptor y agonism and the anti-hyperglycemic activity of thiazolidinediones. J Med Chem 1996;39:665–668.
   PubMed Web of Science ®Google Scholar
• Ranganathan S, Ciaccio PJ, Walsh ES, Tew KD. Genomic sequence of human glyoxalase-I: analysis of promoter activity and its regulation. Gene 1999;240:149–155.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Sen J, Kalia S, Guha-Mukherjee S. Establishment of synchronization in carrot cell suspension culture and studies on stage specific activation of glyoxalase I. Methods Cell Sci 1999;21:141–148.
   Google Scholar
• Mitsumoto A, Kim KR, Oshima G, Nakagawa Y. Inhibitory effects of S-nitrosoglutathione on cell proliferation and DNA synthesis: Possible role of glyoxalase I inactivation. Chem Biol Interact 2001;137:105–121.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab 20001;27: 305–313.
   Google Scholar
• Isley WL. Hepatotoxicity of thiazolidinediones. Expert Opin Drug Saf 2003;2:581–586.
   PubMedGoogle Scholar